Article Text
Abstract
Objective Ovarian cancer (OC) is one of the lethal gynecological malignancies. Most women affected by OC with malignant ascites will relapse. Peptidomics, as an emerging branch of proteomics, is more applied in screening of disease biomarkers, diagnosis, treatment, and monitoring. However, there is still little in-depth analysis about peptidomics study in OC with malignant ascites.
Methods A comparative peptidomic profiling of ascites fluid between 6 OC patients and 6 benign gynecological conditions using liquid chromatography-tandem mass spectrometry was analyzed. Afterward, the Ingenuity Pathway Analysis was performed to reveal the potential function of peptide-protein precursors.
Results A total of 4388 nonredundant peptides were identified, 104 of which were significantly differentially expressed in the ascites fluid of OC and benign gynecological conditions (>2-fold changes and P < 0.05): 52 peptides were upregulated while 52 peptides were downregulated. These peptides were imported into the Ingenuity Pathway Analysis and identified putative roles in OC.
Conclusions We identified the peptidome patterns of patients with OC and benign gynecological conditions, and these differentially expressed that peptides might play an important role during occurrence and development of OC and will be in hope to explore bioactive peptides in the pathogenesis of OC.
- Ovarian cancer
- Malignant ascites
- Peptidomics
- Mass spectrometry
- The Ingenuity Pathway Analysis
Statistics from Altmetric.com
Footnotes
The authors report no conflicts of interest.
The study was funded by a grant from National Natural Science Foundation of China (Grant Number 81501252), Natural Science Foundation of Jiangsu Province (Grant Number BK20140084), and the Medical Science and Technology Development Foundation of Nanjing Department of Health (Grant Number YKK15162).
X.H. and J.Z. performed sample preparation. X.H. and X.Z. analyzed the data. X.H., R.T., and X.Z. wrote the article. S.H. designed the research. X.Z. obtained funding.